Multiple dose administration of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in healthy male subjects

被引：0
|
作者：
Bergman, A
Stevens, C
Zhou, YY
Laethem, M
Lachaert, R
Snyder, K
Hilliard, DR
Tanaka, W
Zeng, W
Wang, A
Chen, L
Winchell, G
Ramael, S
Davies, M
Wagner, J
Herman, G
机构：
来源：
DIABETES | 2005年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A506 / A506
页数：1
相关论文
共 50 条
  • [1] Effect of a single cyclosporine A (NEORAL™) dose on the single-dose pharmacokinetics (PK) of sitagliptin (MK-0431), a dipeptidyl peptidase-IV inhibitor (DPP-IV), in healthy male subjects.
    Krishna, R
    Bergman, AJ
    Larson, P
    Cote, J
    Lasseter, KC
    Pierre, M
    Wang, AQ
    Zeng, W
    Chen, L
    Wagner, JA
    Herman, GA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P63 - P63
  • [2] Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor.
    Bergman, AJ
    Cote, J
    Yi, B
    Wang, AQ
    Zeng, W
    Chen, L
    Marbury, T
    Swan, S
    Smith, W
    Gottesdiener, KM
    Wagner, JA
    Herman, GA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P75 - P75
  • [3] Sitagliptin (MK-0431), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor, does not affect the pharmacokinetics of simvastatin in humans.
    Bergman, AJ
    Cote, J
    Maes, A
    Zhao, J
    Roadcap, B
    Sun, L
    Valesky, R
    Yang, A
    Keymeulen, B
    Wagner, JA
    Herman, GA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P48 - P48
  • [4] Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes
    Scott, R
    Herman, G
    Zhao, P
    Yee, J
    De La Cruz, J
    Wu, L
    Chen, X
    Wu, M
    Stein, P
    [J]. DIABETOLOGIA, 2005, 48 : A287 - A288
  • [5] Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes
    Hanefeld, M
    Herman, G
    Mickej, C
    McGowan, A
    Wu, M
    Zhao, P
    Stein, P
    [J]. DIABETOLOGIA, 2005, 48 : A287 - A287
  • [6] Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes
    Herman, G
    Hanefeld, M
    Wu, M
    Chen, X
    Zhao, P
    Stein, P
    [J]. DIABETES, 2005, 54 : A134 - A134
  • [7] Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor.
    Stevens, C
    Bergman, AJ
    Liu, Q
    Luo, W
    Wang, AQ
    Zeng, W
    Lasseter, KC
    Dilzer, S
    Wagner, JA
    Herman, GA
    Migoya, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P49 - P49
  • [8] Dose-proportionality of sitagliptin (MK-0431), an oral dipeptidyl peptidase-IV inhibitor, in healthy volunteers.
    Bergman, A
    Krishna, R
    Mistry, G
    Luo, W
    Liu, Q
    Stone, J
    Wang, A
    Zeng, W
    Chen, L
    Dilzer, S
    Lasseter, K
    Wagner, J
    Herman, G
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (09): : 1090 - 1090
  • [9] Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D)
    Scott, R
    Herman, G
    Zhao, P
    Chen, X
    Wu, M
    Stein, P
    [J]. DIABETES, 2005, 54 : A10 - A11
  • [10] MK-0431 is a potent, selective, dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Weber, AE
    Kim, D
    Beconi, M
    Eiermann, G
    Fisher, M
    He, HB
    Hickey, G
    Jagpal, S
    Leiting, B
    Lyons, K
    Marsilio, F
    McCann, P
    Moller, D
    Patel, R
    Petrov, A
    Pryor, K
    Roy, RS
    Wu, J
    Wyvratt, M
    Zhang, BB
    Thornberry, NA
    [J]. DIABETES, 2004, 53 : A151 - A151
12345